Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Common Equity (2020 - 2023)

Historic Common Equity for Cullinan Therapeutics (CGEM) over the last 4 years, with Q3 2023 value amounting to $468.8 million.

  • Cullinan Therapeutics' Common Equity fell 2001.46% to $468.8 million in Q3 2023 from the same period last year, while for Sep 2023 it was $468.8 million, marking a year-over-year decrease of 2001.46%. This contributed to the annual value of $535.0 million for FY2022, which is 2577.85% up from last year.
  • Per Cullinan Therapeutics' latest filing, its Common Equity stood at $468.8 million for Q3 2023, which was down 2001.46% from $499.6 million recorded in Q2 2023.
  • Cullinan Therapeutics' Common Equity's 5-year high stood at $604.6 million during Q2 2022, with a 5-year trough of $200.3 million in Q4 2020.
  • For the 4-year period, Cullinan Therapeutics' Common Equity averaged around $466.6 million, with its median value being $469.3 million (2021).
  • As far as peak fluctuations go, Cullinan Therapeutics' Common Equity skyrocketed by 11235.36% in 2021, and later crashed by 2001.46% in 2023.
  • Cullinan Therapeutics' Common Equity (Quarter) stood at $200.3 million in 2020, then soared by 112.35% to $425.4 million in 2021, then rose by 25.78% to $535.0 million in 2022, then dropped by 12.38% to $468.8 million in 2023.
  • Its Common Equity stands at $468.8 million for Q3 2023, versus $499.6 million for Q2 2023 and $485.6 million for Q1 2023.